View of COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH FIRST-LINE AFATINIB VERSUS OSIMERTINIB IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION IN VIETNAM

Return to Article Details COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH FIRST-LINE AFATINIB VERSUS OSIMERTINIB IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION IN VIETNAM Download Download PDF